1. Home
  2. OP vs PRPO Comparison

OP vs PRPO Comparison

Compare OP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • PRPO
  • Stock Information
  • Founded
  • OP 2021
  • PRPO N/A
  • Country
  • OP Greece
  • PRPO United States
  • Employees
  • OP N/A
  • PRPO N/A
  • Industry
  • OP
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • OP
  • PRPO Industrials
  • Exchange
  • OP Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • OP 8.5M
  • PRPO 9.9M
  • IPO Year
  • OP N/A
  • PRPO N/A
  • Fundamental
  • Price
  • OP $1.13
  • PRPO $7.38
  • Analyst Decision
  • OP
  • PRPO
  • Analyst Count
  • OP 0
  • PRPO 0
  • Target Price
  • OP N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • OP 11.4K
  • PRPO 5.7K
  • Earning Date
  • OP 12-20-2024
  • PRPO 03-28-2025
  • Dividend Yield
  • OP N/A
  • PRPO N/A
  • EPS Growth
  • OP N/A
  • PRPO N/A
  • EPS
  • OP N/A
  • PRPO N/A
  • Revenue
  • OP $25,729,000.00
  • PRPO $17,411,000.00
  • Revenue This Year
  • OP N/A
  • PRPO $75.18
  • Revenue Next Year
  • OP N/A
  • PRPO N/A
  • P/E Ratio
  • OP N/A
  • PRPO N/A
  • Revenue Growth
  • OP 36.33
  • PRPO 31.31
  • 52 Week Low
  • OP $1.02
  • PRPO $4.31
  • 52 Week High
  • OP $3.15
  • PRPO $7.55
  • Technical
  • Relative Strength Index (RSI)
  • OP 42.81
  • PRPO 67.04
  • Support Level
  • OP $1.11
  • PRPO $6.65
  • Resistance Level
  • OP $1.18
  • PRPO $7.55
  • Average True Range (ATR)
  • OP 0.04
  • PRPO 0.24
  • MACD
  • OP 0.00
  • PRPO 0.07
  • Stochastic Oscillator
  • OP 18.52
  • PRPO 86.59

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: